ReviewTranslational cancer research2021
Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review.
Review in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- NCBP1 promotes the malignant progression of Wilms' tumor through stabilization of KPNA2 mRNA.Cancer gene therapy · 2026Article
- Review
- Article
- Targeted therapy for Wilms tumor: a bibliometric study of worldwide scientific activity and collaborative networks.Discover oncology · 2025Article
- Wilms' Tumor: A Review of Clinical Characteristics, Treatment Advances, and Research Opportunities.Medicina (Kaunas, Lithuania) · 2025Review
- Paediatric Renal Tumors: A State-of-the-Art Review.Current oncology reports · 2025Review
- Construction of a Wilms tumor risk model based on machine learning and identification of cuproptosis-related clusters.BMC medical informatics and decision making · 2024Article
- Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.Biomedicines · 2024Review
- Screening of potential hub genes involved in Kidney Wilms tumor via bioinformatics analysis and experimental validation.BMC cancer · 2024Article
- Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.Cancers · 2024Review
- Article
- Article
- Cancer immunotherapy of Wilms tumor: a narrative review.Future oncology (London, England) · 2024Review
- Bilateral Wilms Tumor - Case Report of a Patient with Family History.The application of clinical genetics · 2024Article
- Identification of m6A-associated genes as prognostic and immune-associated biomarkers in Wilms tumor.Discover oncology · 2023Article
- Modern treatment strategies in pediatric oncology and hematology.Discover oncology · 2023Review
- Alterations of miRNA Expression in Diffuse Hyperplastic Perilobar Nephroblastomatosis: Mapping the Way to Understanding Wilms' Tumor Development and Differential Diagnosis.International journal of molecular sciences · 2023Article
- Identification of a 12-Gene Signature and Hub Genes Involved in Kidney Wilms TumorFrontiers in oncology · 2022Article
- Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilms tumor is the most common pediatric abdominal solid tumor, and its treatment has been a focus of research. For now, the 5-year survival rate of children with Wilms tumor is about 90%. It is difficult to make further progress simply by the improvement of the existing treatments (multi-modal therapy). Therefore, targeted therapy and immunotherapy which have high accuracy and few side effects began to be considered for the treatment of Wilms tumor. At present, though targeted therapy and immunotherapy are rarely used in the treatment of Wilms tumor except in clinical trials, there are dozens of clinical trials research them around the world. The sites in targeted therapy research are mainly focused on insulin-like growth factor 2 (IGF2) pathway, anti-angiogenesis, phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, and some miRNAs, etc. And there are three types of study in Wilms tumor immunotherapy, which are inhibition of the COX-2 pathway, chimeric antigen receptor (CAR)-T cell therapy, and multi-tumor associated antigen (TAA)-specific cytotoxic T lymphocytes (CTL) therapy. Among them, the phase I clinical trial of multi-TAA-specific CTL (MTAA-CTL) therapy has been completed, and the results are very satisfactory. In this narrative review, we review the basic research and relevant clinical research on targeted therapy and immunotherapy for Wilms tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.